Ironwood Pharmaceuticals, Inc. (IRWD) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IRWD Revenue Growth
Revenue Breakdown (FY 2025)
IRWD's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
IRWD Revenue Analysis (2014–2025)
As of May 8, 2026, Ironwood Pharmaceuticals, Inc. (IRWD) generated trailing twelve-month (TTM) revenue of $361.5 million, reflecting explosive growth of +158.9% year-over-year. The most recent quarter (Q1 2026) recorded $106.5 million in revenue, up 123.2% sequentially.
Looking at the longer-term picture, IRWD's 5-year compound annual growth rate (CAGR) stands at -5.3%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $442.7 million in 2023.
Revenue diversification analysis shows IRWD's business is primarily driven by Collaborative Arrangements (99%), Collaborative arrangement, collaboration and license agreements (1%), and Royalty (0%). With over half of revenue concentrated in Collaborative Arrangements, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PTGX (-91.5% YoY), ARDX (+18.2% YoY), and CPIX (+2.1% YoY), IRWD has outperformed the peer group in terms of revenue growth. Compare IRWD vs PTGX →
IRWD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IRWDCurrent | $362M | +158.9% | -5.3% | 40.1% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% | |
 CPIX | $45M | +2.1% | +3.5% | -6.3% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% |
IRWD Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $296.2M | -15.7% | $294.3M | 99.4% | $118.8M | 40.1% |
| 2024 | $351.4M | -20.6% | $343.9M | 97.9% | $93.1M | 26.5% |
| 2023 | $442.7M | +7.8% | $436.6M | 98.6% | $-945,430,000 | -213.5% |
| 2022 | $410.6M | -0.8% | $409.2M | 99.7% | $250.3M | 61.0% |
| 2021 | $413.8M | +6.2% | $343.3M | 83.0% | $232.3M | 56.1% |
| 2020 | $389.5M | -9.1% | $386.4M | 99.2% | $142.9M | 36.7% |
| 2019 | $428.4M | +23.6% | $293.0M | 68.4% | $120.1M | 28.0% |
| 2018 | $346.6M | +16.2% | $313.9M | 90.6% | $-238,892,000 | -68.9% |
| 2017 | $298.3M | +8.9% | $278.9M | 93.5% | $-77,385,000 | -25.9% |
| 2016 | $274.0M | +83.2% | $272.1M | 99.3% | $-51,870,000 | -18.9% |
See IRWD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IRWD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IRWD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIRWD — Frequently Asked Questions
Quick answers to the most common questions about buying IRWD stock.
Is IRWD's revenue growth accelerating or slowing?
IRWD revenue is accelerating at +158.9% year-over-year, exceeding the 5-year CAGR of -5.3%. TTM revenue reached $362M. Growth momentum has increased versus prior periods.
What is IRWD's long-term revenue growth rate?
Ironwood Pharmaceuticals, Inc.'s 5-year revenue CAGR of -5.3% reflects the sustained expansion pattern. Current YoY growth of +158.9% is above this long-term average.
How is IRWD's revenue distributed by segment?
IRWD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.